

IN THE CLAIMS:

1. (previously presented) A pharmaceutical composition containing at least one platinum complex with a secondary xanthate.

2. (previously presented) The pharmaceutical composition of claim 1 containing at least one of the following compounds:

Bis(O-isopropyl-dithiocarbonato) platinum (II), Bis(O-(1-ethyl) propyl-dithiocarbonato) platinum (II), Bis(O-(1, 2, 2-trimethyl) propyl-dithiocarbonato) platinum (II), Bis(O-cyclobutyl-dithiocarbonato) platinum (II), Bis(O-cyclopentyl-dithiocarbonato) platinum (II) and/or Bis(O-cyclohexyl-dithiocarbonato) platinum (II).

3. (currently amended) The pharmaceutical composition according to claim 1 ~~or 2~~, comprising additionally one or more of the following compounds: cyclosporine, rapamycin, 15-desoxyspergualin, OKT3 and/or azothioprine.

4. (currently amended) The pharmaceutical composition according to claim 1, ~~2 or 3~~, comprising additionally a cytokine, interferon and/or a further cytostatic agent.

5. (currently amended) The pharmaceutical composition according to claim 4, wherein the additional cytostatic agent is selected from the group consisting of methotrexate, aminopterin, dacarbazine, nitroso urea compounds, fluorouracil, bleomycin, daunomycin, daunorubicin, doxorubicin, mithramycin, and mitomycin C.

6. (currently amended) A method ~~Use of at least one platinum complex with a secondary xanthate for preparing a pharmaceutical composition~~ for treating a cancerous or an autoimmune disease comprising the step of administering a pharmaceutical composition comprising at least one platinum complex with a secondary xanthate.

7. (currently amended) The method of ~~Use of~~ claim 6 wherein the pharmaceutical composition contains at least one of the following compounds: Bis(0-isopropyl-dithiocarbonato) platinum(II), Bis(O-(1- ethyl) propyl-dithiocarbonato) platinum (II), Bis(0- (1, 2,2trimethyl) propyl-dithiocarbonato) platinum(II), Bis(O- cyclobutyl-dithiocarbonato) platinum (II), Bis (0-cyclopentyl-dithiocarbonato) platinum (II) and/or Bis (0-cyclohexyl-dithiocarbonato) platinum (II).

8. (currently amended) The method ~~Use~~ according to claim 6 or 7, wherein the cancerous disease is selected from the group consisting of testicular tumors, ovarian carcinomas, bladder carcinomas, colon carcinomas, prostatic carcinomas, parvocellular and non-parvocellular bronchial carcinomas, carcinomas of the cephalic and cervical parts, carcinomas of the thoracic and abdominal regions, cervical and endometrial carcinomas, sarcomas, melanomas and leukemias.

9. (currently amended) A process for the production of a pharmaceutical composition according to claim 1 ~~any one of claims 1 to 5, wherein characterized in that~~ a compound as defined in claim 1 or 2 and, optionally, one or more of the compounds as defined in any one of claims 3 to 5 are mixed with a pharmaceutically compatible carrier or diluent.